Handa Pharmaceuticals is focused on developing and commercializing high-quality prescription medications, utilizing its entrepreneurial spirit and technical expertise. The company operates in two main areas: proprietary therapeutics aimed at addressing significant unmet patient needs and high-barrier-to-entry generic drugs. This dual approach allows Handa to leverage its scientific and executive leadership team's proven track record in building effective teams and successful pharmaceutical businesses, ensuring a robust product portfolio that meets market demands.

In terms of its product pipeline, Handa Pharmaceuticals has successfully achieved approvals from the U.S. FDA for several medications, including Dexlansoprazole Delayed-Release Capsules and Quetiapine Fumarate Extended-Release Tablets, both in partnership with Par Pharmaceutical. Additionally, the company has received approval from Health Canada for Quetiapine Fumarate Extended-Release Tablets under a partner's name. These achievements highlight Handa's commitment to delivering innovative and effective pharmaceutical solutions while navigating the regulatory landscape effectively.

United States

Handa Pharma is a specialty pharmaceutical company that focuses on developing and commercializing high-quality prescription medications in proprietary therapeutics.

Handa Pharmaceuticals

Company Details